<p>Portage Biotech Inc. (NASDAQ:PRTG - 获取免费报告) 在八月份的空头头寸显著减少。截至 8 月 15 日，空头头寸总计为 7,200 股，较 7 月 31 日的 60,600 股减少了 88.1%。根据平均每日交易量为 881,800 股，目前的空头头寸比率为 0.0 天。公司股票约有 0.1% 被卖空。</p>
<p>获取 <strong>Portage Biotech</strong> 警报：</p>
<h2>Portage Biotech 股价下跌 0.5%</h2>
<p>NASDAQ PRTG 股票在周二的午盘交易中下跌$0.03，报价$6.39。该股交易量为 834,279 股，相比平均交易量 356,332 股有所增加。公司的 50 天移动平均价为$3.70，200 天移动平均价为$6.65。该公司的市值为 1.1375 亿美元，市盈率为-0.77，贝塔系数为 1.47。Portage Biotech 的 52 周最低价为$2.10，最高价为$61.99。</p>
<h2>关于 Portage Biotech（获取免费报告）</h2>
<p>Portage Biotech Inc 是一家临床阶段的免疫肿瘤学公司，从事制药和生物技术产品的研究和开发。其产品管线包括：PORT-2 用于治疗难治性非小细胞肺癌、黑色素瘤和难治性黑色素瘤，目前处于 I 期和 II 期临床试验阶段；PORT-3 用于治疗实体肿瘤，目前处于 I 期临床试验阶段；PORT-6 是 A2AR 抑制剂，用于治疗 A2A 和 A2B 高表达的实体肿瘤，目前处于 Ia 期临床试验阶段；PORT-7 是 A2AR 抑制剂，用于治疗 A2A 和 A2B 高表达的实体肿瘤，目前处于 Ib 期临床试验阶段；PORT-1 是用于治疗晚期软组织肉瘤的肿瘤内溶脂溶液，目前处于 III 期临床试验阶段；PORT-4 是纳米脂质凝胶联合制剂，用于治疗实体肿瘤，目前处于临床前试验阶段；PORT-5 是 VLP-STING，用于治疗实体肿瘤，目前处于临床前试验阶段。</p>
<h2>精选文章</h2>
<ul>
<li>五支我们比 Portage Biotech 更看好的股票</li>
<li>对投资者最重要的沃伦·巴菲特股票：他自己的</li>
<li>研究：退休人员从兼职中赚取多少钱？</li>
<li>最佳 ESG 股票：ESG 投资的 11 支最佳股票</li>
<li>Brinker International 因 EPS 未达预期提供回调机会</li>
<li>什么是 Euro STOXX 50 指数？</li>
<li>Globant 是新兴的人工智能投资，正在扩大其影响力</li>
</ul>
<p><em>此即时新闻警报由叙事科技生成，使用 MarketBeat 的财务数据，旨在为读者提供最快速和准确的报道。本故事在发布前已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 预测拜登退出的人士：“准备迎接 “卡玛拉崩盘”（来自 Paradigm Press）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzQ5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzQ5"/></p>
<h2>现在是否值得投资$1,000 在 Portage Biotech？</h2>
<p>在考虑 Portage Biotech 之前，您需要听到这个。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五支顶级分析师悄悄告诉客户现在购买的股票清单...而 Portage Biotech 不在其中。</p>
<p>尽管 Portage Biotech 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五支股票更值得购买。</p>
<p>查看这五支股票</p>

PRTG

ATON

<p>Portage Biotech Inc. (NASDAQ:PRTG) 在 8 月份空头头寸大幅减少了 88.1%，截至 8 月 15 日，空头售出 7200 股，而 7 月 31 日为 60600 股。目前，该公司股票仅有 0.1% 被做空。平均每日交易量为 881,800 股，导致偿还日比率为 0.0 天。尽管如此，PRTG 股票最近下跌了 0.5%，市值为 7500 万美元，市盈率为-0.77</p>

<p>Portage Biotech Inc. (NASDAQ:PRTG - Get Free Report) was the recipient of a significant decrease in short interest in August. As of August 15th, there was short interest totalling 7,200 shares, a decrease of 88.1% from the July 31st total of 60,600 shares. Based on an average daily trading volume, of 881,800 shares, the short-interest ratio is currently 0.0 days. Approximately 0.1% of the company's stock are sold short.</p>
<div class="lb-trans"><p>Portage Biotech Inc. (NASDAQ:PRTG - 获取免费报告) 在八月份的空头头寸显著减少。截至 8 月 15 日，空头头寸总计为 7,200 股，较 7 月 31 日的 60,600 股减少了 88.1%。根据平均每日交易量为 881,800 股，目前的空头头寸比率为 0.0 天。公司股票约有 0.1% 被卖空。</p>
</div><p>Get <strong>Portage Biotech</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Portage Biotech</strong> 警报：</p>
</div><h2>Portage Biotech Stock Down 0.5 %</h2>
<div class="lb-trans"><h2>Portage Biotech 股价下跌 0.5%</h2>
</div><p>Shares of NASDAQ PRTG traded down $0.03 during midday trading on Tuesday, hitting $6.39. The stock had a trading volume of 834,279 shares, compared to its average volume of 356,332. The business's 50 day moving average is $3.70 and its 200-day moving average is $6.65. The company has a market cap of $113.75 million, a P/E ratio of -0.77 and a beta of 1.47. Portage Biotech has a 52 week low of $2.10 and a 52 week high of $61.99.</p>
<div class="lb-trans"><p>NASDAQ PRTG 股票在周二的午盘交易中下跌$0.03，报价$6.39。该股交易量为 834,279 股，相比平均交易量 356,332 股有所增加。公司的 50 天移动平均价为$3.70，200 天移动平均价为$6.65。该公司的市值为 1.1375 亿美元，市盈率为-0.77，贝塔系数为 1.47。Portage Biotech 的 52 周最低价为$2.10，最高价为$61.99。</p>
</div><h2>About Portage Biotech (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 Portage Biotech（获取免费报告）</h2>
</div><p>Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A &amp; A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A &amp; A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.</p>
<div class="lb-trans"><p>Portage Biotech Inc 是一家临床阶段的免疫肿瘤学公司，从事制药和生物技术产品的研究和开发。其产品管线包括：PORT-2 用于治疗难治性非小细胞肺癌、黑色素瘤和难治性黑色素瘤，目前处于 I 期和 II 期临床试验阶段；PORT-3 用于治疗实体肿瘤，目前处于 I 期临床试验阶段；PORT-6 是 A2AR 抑制剂，用于治疗 A2A 和 A2B 高表达的实体肿瘤，目前处于 Ia 期临床试验阶段；PORT-7 是 A2AR 抑制剂，用于治疗 A2A 和 A2B 高表达的实体肿瘤，目前处于 Ib 期临床试验阶段；PORT-1 是用于治疗晚期软组织肉瘤的肿瘤内溶脂溶液，目前处于 III 期临床试验阶段；PORT-4 是纳米脂质凝胶联合制剂，用于治疗实体肿瘤，目前处于临床前试验阶段；PORT-5 是 VLP-STING，用于治疗实体肿瘤，目前处于临床前试验阶段。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Portage Biotech</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>Study: How Much Are Retirees Earning from Side Hustles in 2024?</li>
<li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li>
<li>Brinker International Offers a Pullback Opportunity on EPS Miss</li>
<li>What is the Euro STOXX 50 Index?</li>
<li>Globant Is an Emerging AI Play That’s Expanding Its Footprint</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>五支我们比 Portage Biotech 更看好的股票</li>
<li>对投资者最重要的沃伦·巴菲特股票：他自己的</li>
<li>研究：退休人员从兼职中赚取多少钱？</li>
<li>最佳 ESG 股票：ESG 投资的 11 支最佳股票</li>
<li>Brinker International 因 EPS 未达预期提供回调机会</li>
<li>什么是 Euro STOXX 50 指数？</li>
<li>Globant 是新兴的人工智能投资，正在扩大其影响力</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科技生成，使用 MarketBeat 的财务数据，旨在为读者提供最快速和准确的报道。本故事在发布前已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Man who Predicted Biden’s Drop Out: “Prepare for “Kamala Crash” (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 预测拜登退出的人士：“准备迎接 “卡玛拉崩盘”（来自 Paradigm Press）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzQ5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9349&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Portage Biotech right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 在 Portage Biotech？</h2>
</div><p>Before you consider Portage Biotech, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Portage Biotech 之前，您需要听到这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Portage Biotech wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五支顶级分析师悄悄告诉客户现在购买的股票清单...而 Portage Biotech 不在其中。</p>
</div><p>While Portage Biotech currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Portage Biotech 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五支股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五支股票</p>
</div>

Portage Biotech Inc.（纳斯达克股票代码：PRTG）的空头头寸减少了 88.1%